Aldeyra Therapeutics: A Buy Rating on Strong Clinical Progress and Market Potential

TipRanksAug 9 07:52 ET · Ratings

Express News | Aldeyra Therapeutics Inc : Jefferies Raises Target Price to $8 From $7

ReutersAug 9 03:39 ET

Buy Recommendation for Aldeyra Therapeutics Amid Positive Phase 3 Results for Reproxalap

TipRanksAug 9 01:25 ET

Aldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease Treatment

WSJAug 8 08:24 ET

Express News | Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 Trial For Reproxalap Ophthalmic Solution In Treating Dry Eye Disease; Statistically Superior For Ocular Discomfort; NDA Resubmission Anticipated In 2024

BenzingaAug 8 07:15 ET

Express News | Aldeyra: No Safety Signals Observed in Clinical Trial, and Reproxalap Was Observed to Be Well Tolerated

ReutersAug 8 07:00 ET